课题基金 / 基金详情

Next generation patient-derived, genetically-defined prostate cancer xenograft models for anti- cancer drug development

Next generation patient-derived, genetically-defined prostate cancer xenograft models for anti- cancer drug development
用于抗癌药物开发的下一代源自患者、基因定义的前列腺癌异种移植模型
批准号:
238170
负责人:
Wang Yuzhuo
金额:
$27.32万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2011
资助国家:
加拿大
项目状态:
已结题
起止时间:
2011-09-01 至 2014-09-01

项目摘要

项目成果

Wang Yuzhuo的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Evaluation of potential anticancer drugs is - at present - commonly carried out with preclinical cancer models that consist of special, immuno-deficient mice carrying grafts of cultured human cancer cells available commercially. While such commercial canc
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A master transcription factor driving cell lineage reprogramming in neuroendocrine prostate cancer development and progression
  • 批准号:
    472404
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2022
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
Optimization and Validation of MCT4-targeting Small Molecule Inhibitors for Treatment of Advanced Cancers
  • 批准号:
    451866
  • 项目类别:
    Operating Grants
  • 资助金额:
    $83.6万
  • 财政年份:
    2021
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
The role of PRDM16 in neuroendocrine prostate cancer development and aggressiveness
  • 批准号:
    420178
  • 项目类别:
    Operating Grants
  • 资助金额:
    $55.73万
  • 财政年份:
    2020
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
Function and therapeutic potential of SUV420H2 in neuroendocrine prostate cancer
  • 批准号:
    390460
  • 项目类别:
    Operating Grants
  • 资助金额:
    $69.66万
  • 财政年份:
    2018
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
海外基金